Solosec (secnidazole) step therapy program
UnitedHealthcare step therapy program requiring trial of specified alternative antibacterial agents before coverage of Solosec (secnidazole) for bacterial vaginosis or trichomoniasis in patients >=12 years. Authorization issued for one month; automated approval based on claims history may be used.
8/2024 annual review with no changes.
Added Cleocin vaginal suppositories as a step agent (3/2019 historic change).
Added new indication for Trichomonas vaginalis (8/2022).
Added statement regarding use of automated approval process (3/2020).
Coverage Summary
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.